

Biologic Studies Group -COVID-19, The University of Manchester

First published: 14/04/2010

Last updated: 20/08/2024

Institution


Educational Institution

Institution identification

Institution ID

39566

Institution countries

 United Kingdom

Type of institution

Educational Institution

Institution website

<https://sites.manchester.ac.uk/biologic-studies-group/>

ENCePP partner

No

Institution description

Biologic Studies Group: This group is part of the Versus Arthritis Centre for Epidemiology and hosts a number of UK national biologic and Other new targeted drug registers. The primary aim of these studies is to investigate the long-term safety of these newer therapies. The group consists of the following studies: 1. BSRBR-RA - The British Society for Rheumatology Biologics Register - Rheumatoid Arthritis 2. BADBIR - The British Association of Dermatologists' Biologic Interventions Register 3. BSPAR EN - Study of Enbrel in Children with JIA 4. BCRD - Arthritis Research UK Study of Biologics in Children with Rheumatic Diseases 5. BILAG BR - Biologics Register Prospective Cohort Study of Lupus 6. BRAGGSS - Biologics in Rheumatoid Arthritis Genetics and Genomics Study

Syndicate Expertise: The main areas of expertise include the epidemiology and genetics of rheumatic disease, pharmacovigilance and pharmacoepidemiology.

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Watson Kath kath.watson@manchester.ac.uk



kath.watson@manchester.ac.uk